BCG in combination with durvalumab in adult BCG-naïve, high-risk NMIBC participants

Trial Identifier: D419JC00002
Sponsor: AstraZeneca
Collaborator:
Parexel
Start Date: August 2023
Primary Completion Date: June 2025
Study Completion Date: May 2027

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
US, AR Little Rock, AR, US, 72211
US, AZ Phoenix, AZ, US, 85054
US, CA San Diego, CA, US, 92123
US, CO Lakewood, CO, US, 80228
US, FL Hialeah, FL, US, 33016
US, FL Jacksonville, FL, US, 32209
US, IN Greenwood, IN, US, 46143
US, KS Wichita, KS, US, 67226
US, MD Baltimore, MD, US, 21203
US, MD Hanover, MD, US, 21076
US, MI Royal Oak, MI, US, 48073
US, MI Troy, MI, US, 48084
US, NY Syracuse, NY, US, 13210
US, OH Cincinnati, OH, US, 45212
US, PA Bala Cynwyd, PA, US, 19004-1017
US, SC Myrtle Beach, SC, US, 29572
US, TN Nashville, TN, US, 37209
US, TX Austin, TX, US, 78759
US, WA Spokane, WA, US, 99202